Vimarsana
Biggest News Aggregation in the World

Page 2 - Small Molecule News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Small Molecule. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Small Molecule Today - Breaking & Trending Today

Super Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed InsightAce Latest Study - Vimarsana News

Super Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed InsightAce Latest Study

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Super Generics Market –By Therapeutic Area...

Outrun emerges from stealth with $10M for E3 ligase inhibitors - Vimarsana News

Outrun emerges from stealth with $10M for E3 ligase inhibitors

Newco Outrun Therapeutics Ltd. has raised $10 million in a seed round to develop small-molecule E3 ubiquitin ligase inhibitors that prevent programmed protein degradation. The lead program targeting an E3 ligase that tags a tumor suppressor protein for destruction will now advance to preclinical development.

Cerevel undersell? Bombshell Parkinson's phase III with tavapadon - Vimarsana News

Cerevel undersell? Bombshell Parkinson's phase III with tavapadon

Cerevel Therapeutics Inc.’s positive results from the long-shot pivotal phase III Tempo-3 trial with tavapadon – the first D1/D5 receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease – added gravy to the $8.7 billion takeover by Abbvie Inc., disclosed late last year. The buyout’s centerpiece was the late-stage asset emraclidine, a positive allosteric modulator of the muscarinic M4 receptor, touted as a potential best-in-class, next-generation antipsychotic for schizophrenia, which strikes more than 5 million people in the G7 (U.S., France, Germany, ...

Global Small Molecule Drug Delivery and Formulation - Vimarsana News

Global Small Molecule Drug Delivery and Formulation

Dublin, April 04, 2024 (GLOBE NEWSWIRE) -- The

Rx, med-tech industry groups warn of impact of Gilead R&D suits - Vimarsana News

Rx, med-tech industry groups warn of impact of Gilead R&D suits

The U.S. biopharma and med-tech industries are adding their voice to that of Gilead Sciences Inc. in urging the California Supreme Court to review the Gilead Tenofovir Cases, which seek to hold the drug company liable for how and when it developed its pipeline of HIV drugs.